MNRR1/CHCHD2 and Mitochondrial Dysfunction in Disease
Dr. Lawrence Grossman, Wayne State University, USA will join the Targeting Mitochondria 2023 Congress and give a presentation entitled "MNRR1/CHCHD2 and Mitochondrial Dysfunction in Disease".
MNRR1 levels are reduced in several diseases that contain mitochondrial dysfunction. Either genetic or pharmacological restoration of MNRR1 levels also restores function, both in a cell and an animal model. The disease induced reduction of MNRR1 takes place by both transcriptional and post transcriptional mechanisms in different disease models.
Join Targeting Mitochondria 2023 to learn more about Dr. Grossman's exciting talk. You can submit a related abstract here.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Why a WMS Task Force?
Prof. Marvin Edeas, Institut Cochin, Université de Paris, France, will join Targeting Mitochondria 2023 to explain further on : "Why a WMS Task Force?".
Join Targeting Mitochondria 2023 to learn more about Prof. Edeas's interesting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Mitochondrial Transplantation: What's Next?
Dr. James D. McCully, from The Harvard Medical School Department of Cardiac Surgery Boston Children’s Hospital, USA, will join us this year to present his most recent findings: "Mitochondrial Transplantation What's Next?".
Join Targeting Mitochondria 2023 to learn more about Dr. McCully's interesting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Targeting Mitochondria Based on Mitochondrial Drug Delivery Systems (DDS)
Under its guiding slogan “The future of medicine will come through mitochondria”, the World Mitochondria Society proudly presents Targeting Mitochondria 2023 speakers. This conference gathers the brightest minds, leaders and actors in mitochondrial research.
At the forefront of this gathering is Prof. Yuma Yamada of the Faculty of Pharmaceutical Sciences, Hokkaido University, who will give a standout presentation on “Targeting Mitochondria Based on Mitochondrial Drug Delivery Systems (DDS).” Prof. Yamada’s recent recognition as the recipient of the American Pharmacists Association’s 2022 Ebert Prize—the oldest and one of the most prestigious pharmacy awards in the US—further cements his standing in the field.
A Significant Advancement in Mitochondrial Research: The MITO-Porter
Addressing challenges that have spanned a decade in mitochondrial drug delivery, Prof. Yamada’s development of the MITO-Porter is especially noteworthy. This cutting-edge nano DDS is meticulously engineered to transport macromolecular cargos directly into mitochondria via membrane fusion. The MITO-Porter represents not just a technological marvel but a beacon for the future of mitochondrial medicine.
Although various mitochondrial drug delivery systems have emerged over the years, many have encountered hurdles. The MITO-Porter, with its groundbreaking approach, navigates these challenges, heralding a new era of therapeutic potential.
In his presentation, Prof. Yamada will provide an in-depth overview of the MITO-Porter, elucidating its design, capabilities, and forward-looking applications. Attendees will be enriched with insights into the contemporary landscape of mitochondrial DDS and will experience the profound impact of the MITO-Porter in the domain of mitochondrial therapy.
Join Targeting Mitochondria 2023 to learn more about Prof. Yamada's interesting talk.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Targeting Mitochondrial Activity in Liver in Disease: Barriers and Perspectives
Prof. María Luz Martínez-Chantar, CIC bioGUNE, Spain, will join Targeting Mitochondria 2023 to present a talk entitled: "Targeting Mitochondrial Activity in Liver in Disease: Barriers and Perspectives".
Mitochondrial dysfunction is a critical factor contributing to the pathogenesis and progression of chronic liver diseases. This study conducted by Prof. Martínez-Chantar aims to elucidate key players, causative factors, and consequences of mitochondrial dysfunction in the context of liver health.
Specifically, she and her team explore the potential therapeutic benefits of enhancing mitochondrial activity by modulating genes related to the electron transport chain, mitochondrial metabolism and cation modulators in the liver.
The findings provide compelling evidence supporting different genes as a promising therapeutic approach that not only ameliorates liver injury but also fosters liver regeneration.
Join Targeting Mitochondria 2023 to learn more about Prof. Martínez-Chantar's interesting findings.
About Prof. Martinez-Chantar
Professor Martinez-Chantar has an extensive experience in the study of liver biology and disease with a high-level track of productivity in the 1st decile journals like Nature Communications, Cell Metabolism, Hepatology, Journal of Hepatology and Gastroenterology. She has been continuously supported by competitive public and private funding, both national and international, including NIH. She coordinates the Translational Area of the National Institute for the study of Liver & Gastrointestinal Diseases and is in the SAB of the Molecular Medicine Center Nice, IDIVAL and IDIBAPS. She shows extensive participation in different networks (CibereHD, Women in Hepatology: International Consortium, Hepamet Registry, MetaboCancer Excellence Network and diverse EU COST actions). Her contracts with pharmas, as AGIOS, Mitotherapeutix, Takeda or Silence Therapeutics, led to 5 patent applications and 4 licensed products. Her collaboration with OWL Metabolomics led to the development of OWLiver® Care and OWLiver®, non-invasive assays for NASH diagnosis.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Dr. Naig Gueguen announces the Agenda of the Upcoming Workshop on Mitochondrial Function and Dysfunction Evaluation
In association with the World Mitochondria Society (WMS), we are thrilled to announce the hosting of a specialized workshop focused on the Evaluation of Mitochondria Function, Dysfunction, and Activities. The workshop will take place on October 11, 2023, one day prior to the start of the Targeting Mitochondria 2023 Congress.
Purpose of the Workshop
This workshop will delve into the significant role mitochondria play in various medical fields, including cardiology, neurology, nephrology, and infectious diseases, among others. Given the centrality of mitochondria to human metabolism, their assessment is vital for the discovery of treatments for diseases associated with mitochondrial dysfunction.
Workshop Key Objectives
- To introduce and review technological tools used for mitochondrial study and analysis.
- To provide an understanding of mitochondrial markers evaluated in the context of medical research.
- To present various methodologies for analyzing mitochondria and their functions, including bioenergetics, biogenesis, dynamics, and mitophagy.
- To discuss biochemical diagnostic strategies for mitochondrial diseases.
- To discuss practical cases to solidify understanding.
Who Can Attend?
The workshop welcomes everyone looking to enhance their understanding and proficiency in the field of mitochondria, metabolism, and bioenergetics, their vital roles within the human body, as well as the latest innovations in therapeutic tools and analyses.
About Dr. Naig Gueguen:
Dr. Gueguen is an expert from the Mitovasc Institute, Mitolab team, and member of INSERM 1083, CNRS 6215, Centre Hospitalier Universitaire d’Angers. She will eagerly anticipate this enriching workshop. The Mitovasc Institute's Mitolab Team is renowned worldwide for its work in mitochondrial research. The team focuses on studying mitochondrial function and dysfunction, with the aim of developing effective treatments for various diseases.
Contact WMS: This email address is being protected from spambots. You need JavaScript enabled to view it.
Mitochondrial Presequence Protein Translocation
Prof. Nils Wiedemann, Universität Freiburg, Germany, will join Targeting Mitochondria 2023 to present a talk entitled: "Mitochondrial Presequence Protein Translocation".
Virtually all of the ~1,000 different mitochondrial proteins are synthesised in the cytosol and must be imported into the organelle. Most of these mitochondrial precursor proteins contain an amino-terminal presequence, which forms a positively charged amphiphilic alpha-helix. The TIM23 translocase sorts these presequence proteins into the inner membrane or matrix. Prof. Wiedemann and colleagues mapped the interaction of the essential subunit Tim17 with presequence containing precursor proteins.Tim17 contains conserved negative charged residues close to the intermembrane space side of the inner membrane, which are essential for presequence protein translocation along a distinct transmembrane cavity of the Tim17-bilayer interface.
About Prof. Wiedemann,
Professor (apl.) of Biochemistry and Molecular Biology, University of Freiburg, Germany
Prof. Wiedmann won the Young Investigator Award, German Society for Biochemistry and Molecular Biology (GBM) Frankfurt in the year 2007.
Join Targeting Mitochondria 2023 to learn more about Prof. Wiedemann's interesting findings. Read more about Prof. Wiedmann's latest research.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
Cholesterol: Why Have Mitochondrial Biologists Ignored this Critical Mitochondrial Component for Over a Century?
Prof. Ian Holt, active member of the scientific committee, Instituto de Investigación Sanitaria Biodonostia, Spain, will join Targeting Mitochondria 2023 to present a talk titled: "Cholesterol: Why Have Mitochondrial Biologists Ignored this Critical Mitochondrial Component for Over a Century?".
As Michael Brown noted in his 1985 Nobel Lecture: Cholesterol is the most highly decorated small molecule in biology. However, cholesterol’s contribution to mitochondrial membranes has attracted little interest, as they are ‘cholesterol-poor organelles’ with 0.5-3% of the content found in the plasma membrane. And although high cholesterol has been linked to mitochondrial dysfunction, this merely implied that mitochondria have an aversion to cholesterol.
The first forays into this field came with the unexpected discovery that pathological mutant forms of the trans-mitochondrial membrane protein, ATAD3, completely reconfigure cellular cholesterol metabolism.
During Targeting Mitochondria 2023, Prof. Holt will report the central role of cholesterol in the ATAD3 disease cascade, and crucially show that the molecular phenotypes stem from the mitochondrion’s absolute requirement for cholesterol.
Join Targeting Mitochondria 2023 to learn more about Prof. Holt's interesting findings.
Targeting Mitochondria 2023 Congress
October 11-13, 2023 - Berlin, Germany
